{"id":389171,"date":"2023-08-14T00:00:00","date_gmt":"2023-08-14T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/biosbi0007-2023-biopharma-biosimilars-access-reimbursement-us-eu-2023\/"},"modified":"2026-03-31T10:32:25","modified_gmt":"2026-03-31T10:32:25","slug":"biosbi0007-2023-biopharma-biosimilars-access-reimbursement-us-eu-2023","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/biosbi0007-2023-biopharma-biosimilars-access-reimbursement-us-eu-2023\/","title":{"rendered":"Biosimilars | Access &#038; Reimbursement | US\/EU | 2023"},"content":{"rendered":"<p>Payers play a significant role in determining the commercial success of biosimilars\u2014as well as their reference brands\u2014as they decide which products are granted formulary access and preferential reimbursement. Although biosimilars such as Pfizer\u2019s Inflectra and Retacrit are available both in Europe and the United States, their success may vary because of regional differences in the drivers of and barriers to biosimilar uptake. As such, it is necessary for biosimilars developers and manufacturers of branded biologics to understand which factors influence payer decisions regarding biosimilars.<\/p>\n<p><strong>Questions answered: <\/strong><\/p>\n<ul>\n<li>What are payers\u2019 perspectives on the drivers of and barriers to biosimilars uptake?<\/li>\n<li>What factors influence which biosimilars are preferred on formularies in the United States?<\/li>\n<li>How do payers choose among multiple biosimilars of the same brand in the EU?<\/li>\n<li>What strategies do payers use to manage biosimilars?<\/li>\n<li>What expectations do payers have for biosimilars discounts?<\/li>\n<li>How would the availability of biosimilars influence the pricing of emerging agents?<\/li>\n<li>Will payer strategies for biosimilars differ between therapeutic specialties?<\/li>\n<li>Has COVID-19 affected the use or coverage of biosimilars?<\/li>\n<\/ul>\n<p><strong>Key markets covered: <\/strong><\/p>\n<ul>\n<li>France<\/li>\n<li>Germany<\/li>\n<li>Italy<\/li>\n<li>Spain<\/li>\n<li>United Kingdom<\/li>\n<li>United States<\/li>\n<\/ul>\n<p><strong>Key companies mentioned: <\/strong><\/p>\n<ul>\n<li>Amgen<\/li>\n<li>Biocon<\/li>\n<li>Biogen<\/li>\n<li>Boehringer Ingelheim<\/li>\n<li>Celltrion<\/li>\n<li>Eli Lilly<\/li>\n<li>Janssen<\/li>\n<li>Johnson &#038; Johnson<\/li>\n<li>Merck &#038; Co.<\/li>\n<li>Mundipharma<\/li>\n<li>Viatris (Mylan)<\/li>\n<li>Novartis<\/li>\n<li>Pfizer<\/li>\n<li>Roche<\/li>\n<li>Samsung Bioepis<\/li>\n<li>Sandoz<\/li>\n<li>Sanofi<\/li>\n<li>Teva<\/li>\n<\/ul>\n<p><strong>Key drugs mentioned: <\/strong><\/p>\n<ul>\n<li>Admelog \/ Insulin Lispro Sanofi<\/li>\n<li>Aranesp<\/li>\n<li>Avastin<\/li>\n<li>Avsola<\/li>\n<li>Basaglar \/ Abasaglar<\/li>\n<li>Benepali<\/li>\n<li>Binocrit<\/li>\n<li>Enbrel<\/li>\n<li>Flixabi<\/li>\n<li>Fulphila<\/li>\n<li>Herceptin<\/li>\n<li>Herzuma<\/li>\n<li>Hulio<\/li>\n<li>Humalog<\/li>\n<li>Humira<\/li>\n<li>Inflectra<\/li>\n<li>Kanjinti<\/li>\n<li>Lantus<\/li>\n<li>Levemir<\/li>\n<li>Mvasi<\/li>\n<li>Neulasta<\/li>\n<li>Neupogen<\/li>\n<li>Nivestim \/ Nivestym<\/li>\n<li>NovoLog \/ NovoRapid<\/li>\n<li>Nyvepria<\/li>\n<li>Ogivri<\/li>\n<li>Ontruzant<\/li>\n<li>Procrit \/ Epogen<\/li>\n<li>Remicade<\/li>\n<li>Remsima<\/li>\n<li>Retacrit<\/li>\n<li>Riabni<\/li>\n<li>Rituxan \/ MabThera<\/li>\n<li>Ruxience<\/li>\n<li>Semglee<\/li>\n<li>Trazimera<\/li>\n<li>Truxima<\/li>\n<li>Udenyca<\/li>\n<li>Zarzio \/ Zarxio<\/li>\n<li>Ziextenzo<\/li>\n<li>Zirabev<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-389171","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-product-biosimilars","biopharma-geography-us","biopharma-date-975"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389171","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389171\/revisions"}],"predecessor-version":[{"id":576079,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389171\/revisions\/576079"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=389171"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}